Image de l'actualité
![](/sites/default/files/styles/image_actualite/public/2018-04/Capture%20d%E2%80%99%C3%A9cran%202018-02-14%20%C3%A0%2017.38.17.png?itok=GK7BpC-0)
Date de parution
Contenu texte de l'actualité
The American Food and Drug Administration (FDA) has granted Orphan Drug Designation to ZENEO® Midazolam for the treatment of status epilepticus (epileptic seizure lasting longer than 5 minutes).
The orphan designation for ZENEO® Midazolam improves Crossject’s international visibility and gives impetus to its current negotiations for partnerships with pharmaceutical laboratories.
Read more on the section "Press release".